A detailed history of Bank Of America Corp transactions in Celcuity Inc. stock. As of the latest transaction made, Bank Of America Corp holds 277,352 shares of CELC stock, worth $3.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
277,352
Previous 230,595 20.28%
Holding current value
$3.54 Million
Previous $3.78 Million 9.48%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.98 - $19.15 $653,662 - $895,396
46,757 Added 20.28%
277,352 $4.14 Million
Q2 2024

Aug 14, 2024

SELL
$14.1 - $20.78 $139,716 - $205,909
-9,909 Reduced 4.12%
230,595 $3.78 Million
Q1 2024

May 15, 2024

BUY
$13.74 - $21.6 $3.03 Million - $4.77 Million
220,819 Added 1121.76%
240,504 $5.19 Million
Q4 2023

Feb 14, 2024

BUY
$8.7 - $15.02 $63,318 - $109,315
7,278 Added 58.66%
19,685 $286,000
Q2 2023

Aug 14, 2023

BUY
$9.39 - $12.18 $45,823 - $59,438
4,880 Added 64.83%
12,407 $136,000
Q1 2023

May 12, 2023

BUY
$9.4 - $12.82 $41,059 - $55,997
4,368 Added 138.27%
7,527 $77,000
Q4 2022

Feb 10, 2023

BUY
$7.55 - $14.01 $6,847 - $12,707
907 Added 40.28%
3,159 $44,000
Q3 2022

Nov 14, 2022

BUY
$8.0 - $10.64 $17,960 - $23,886
2,245 Added 32071.43%
2,252 $23,000
Q2 2022

Aug 12, 2022

SELL
$5.35 - $10.11 $24,401 - $46,111
-4,561 Reduced 99.85%
7 $0
Q1 2022

May 16, 2022

SELL
$7.93 - $13.33 $8,215 - $13,809
-1,036 Reduced 18.49%
4,568 $43,000
Q4 2021

Feb 08, 2022

BUY
$11.96 - $19.35 $38,738 - $62,674
3,239 Added 136.96%
5,604 $74,000
Q3 2021

Nov 15, 2021

BUY
$17.35 - $24.87 $11,190 - $16,041
645 Added 37.5%
2,365 $43,000
Q2 2021

Sep 13, 2021

BUY
$14.25 - $30.93 $24,510 - $53,199
1,720 New
1,720 $41,000

Others Institutions Holding CELC

About Celcuity Inc.


  • Ticker CELC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,941,300
  • Market Cap $191M
  • Description
  • Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...
More about CELC
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.